Anti-Depressant Therapy Brightens the Outlook for Prostate Cancer Bone Metastases

Michael D Nyquist; Peter S Nelson

doi:10.1016/j.ccell.2017.02.012

Anti-Depressant Therapy Brightens the Outlook for Prostate Cancer Bone Metastases

Cancer Cell. 2017 Mar 13;31(3):303-305. doi: 10.1016/j.ccell.2017.02.012.

Authors

Michael D Nyquist¹, Peter S Nelson²

Affiliations

¹ Divisions of Human Biology and Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
² Divisions of Human Biology and Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA; Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA 98195, USA. Electronic address: [email protected].

PMID: 28292431
DOI: 10.1016/j.ccell.2017.02.012

Abstract

In this issue of Cancer Cell, Wu et al. identify MAOA as a key mediator of osteolytic bone responses that involve complex paracrine interactions between tumor cells, osteoblasts, and osteoclasts. Pharmacological inhibition of MAOA enzymatic activity effectively interrupted osteolysis and metastatic progression in preclinical models, suggesting a new treatment opportunity.

Publication types

Comment

MeSH terms

Bone Neoplasms*
Cell Line, Tumor
Humans
Male
Osteoblasts
Osteoclasts / drug effects
Osteolysis*
Prostatic Neoplasms